Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

NCT07316686 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer (Adenocarcinoma)

Interventions

DRUG: Docetaxel 50mg/m2
DRUG: Docetaxel 60mg/m2
DRUG: Docetaxel 75 mg/m²
RADIATION: 177Lu-PSMA-I&T

Sponsor

Instituto do Cancer do Estado de São Paulo